{"ticker": {"uuid": "3825ed27-7e07-4359-865d-efd7143dd0b9", "symbol": "2566", "name": "Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.", "exchange": "HKG", "country": "HK", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. commences an Equity Buyback Plan for 24,151,640 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2026.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxORjFhaUJHSVV1blNaY3Fza29FaWFaNlRDYlQycWNpbmFySHJLamQzUEVNb2RfNDgxWXJ3NWZjRWZuODRaTEM3dEx3MlRkZjFhUFFCVzRVRUFRNG9WOExwTzNRZFY5Qzl5Wmc3aFJpeU9QVmwzV3cxcldDekttMDZsY1Z5TGxQTHdyeTJoNXRNVFVMaDgyVFJra1dVNzYxcWY5QVU5ZDhVQ2dSVjd2ejdCTW42WnJqSlhDaVhkZllsRVZJXzROZ3V5R2NBeldKc3FYMzhxUXEzeTlpcXRCUG1TaTk0V2s?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiuyuan Gene raises HKD$485M in Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPM3NDY2ZOeV9lX3luTDNoVnF1MkdWbzFmOG1NMWo0WENTenRaZ2l4MW5ITWZpV3owQXIwSVphM3lKSk8wajRZYTZXRFNIbXg1U2tiUHJQNFVDRHQ2TFNwLXIzQlg5VmlqeVVvZ196NWJReENST3ZheHJpVldoSnhHUnhhSFlLV2dxR3BqdC1n?oc=5", "source_name": "BioWorld News", "published_at": "2024-12-03T08:00:00+00:00", "published_display": "03 Dec 2024 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. commences an Equity Buyback Plan for 24,151,640 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2026.", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxORjFhaUJHSVV1blNaY3Fza29FaWFaNlRDYlQycWNpbmFySHJLamQzUEVNb2RfNDgxWXJ3NWZjRWZuODRaTEM3dEx3MlRkZjFhUFFCVzRVRUFRNG9WOExwTzNRZFY5Qzl5Wmc3aFJpeU9QVmwzV3cxcldDekttMDZsY1Z5TGxQTHdyeTJoNXRNVFVMaDgyVFJra1dVNzYxcWY5QVU5ZDhVQ2dSVjd2ejdCTW42WnJqSlhDaVhkZllsRVZJXzROZ3V5R2NBeldKc3FYMzhxUXEzeTlpcXRCUG1TaTk0V2s?oc=5", "source_name": "marketscreener.com", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Jiuyuan Gene raises HKD$485M in Hong Kong IPO", "summary": "", "url": "https://news.google.com/rss/articles/CBMijgFBVV95cUxPM3NDY2ZOeV9lX3luTDNoVnF1MkdWbzFmOG1NMWo0WENTenRaZ2l4MW5ITWZpV3owQXIwSVphM3lKSk8wajRZYTZXRFNIbXg1U2tiUHJQNFVDRHQ2TFNwLXIzQlg5VmlqeVVvZ196NWJReENST3ZheHJpVldoSnhHUnhhSFlLV2dxR3BqdC1n?oc=5", "source_name": "BioWorld News", "published_at": "2024-12-03T08:00:00+00:00", "published_display": "03 Dec 2024 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 78, "total_relevant": 2, "sentiment_summary": {"positive": 1, "negative": 0, "neutral": 1, "score": 58, "total": 2, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "capital_return", "primary_label": "Capital return", "confidence": 58, "events": [{"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "general", "label": "Market update", "weight": 0.55, "count": 1}], "positive_events": 1, "negative_events": 0}, "market_context": {"has_market_context": true, "latest_close": 6.34, "latest_week": "2026-07-10", "one_week_move": -3.6, "four_week_move": 23.3, "twelve_week_move": -10.6, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.239568, "market_dynamics_buy_signal": false, "relative_strength": -23.11387, "fair_value_gap": -20.8, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.3503, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.6% over one week, +23.3% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 60, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Capital return", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "marketscreener.com", "count": 1}, {"label": "BioWorld News", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 2}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Capital return", "count": 1}, {"label": "Market update", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "58/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Capital return", "tone": "neutral", "text": "58/100 classification confidence."}, {"label": "Company focus", "value": "2", "tone": "neutral", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-3.6% over one week, +23.3% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. commences an Equity Buyback Plan for 24,151,640 shares, representing 10% of its issued share capital, under the authorization approved on June 15, 2026."}], "updated_at": "2026-07-17T23:57:12.026089+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}